کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8924788 | 1643562 | 2017 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
NGSCtDNATKIStriatin - استریاتینMRI - امآرآی یا تصویرسازی تشدید مغناطیسیMagnetic resonance imaging - تصویربرداری رزونانس مغناطیسیNext-generation sequencing - تعیین توالی نسل بعدیNon–small cell lung cancer - سرطان ریه سلول غیر سلولیNSCLC - سرطان ریوی غیر سلول کوچکTyrosine kinase inhibitor - مهار کننده تیروزین کینازcirculating tumor DNA - گردش DNA تومور
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
مراقبت های ویژه و مراقبتهای ویژه پزشکی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The ALK gene fusion has been identified as a new driver gene in non-small cell lung cancer (NSCLC). It includes the EML4-ALK rearrangement as a recurring event that renders the tumor sensitive to ALK tyrosine kinase inhibitor crizotinib. In addition, several other fusion partners to ALK kinase domain (eg, TFG, KLC1, and KIF5B) have been identified in NSCLC. However, clinical data relevant to response in lung cancer harboring these rare ALK translocations are not fully available. A nonsmoking Chinese male originally diagnosed with “stage Ib lung adenocarcinoma” showed metastases in regional lymph nodes, pleura, and bone 1 year after surgery. The patient refused invasive tissue biopsy, and chemotherapy was administrated, which failed as a first- and second-line treatment. We then identified a rare fusion gene of ALK and Striatin (STRN) using next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) analysis. The NGS of the patient's originally paraffin-embedded surgical tumor samples also indicated the fusion. Reverse transcription-polymerase chain reaction and Sanger sequencing further confirmed the results. The STRN-ALK involves the fusion of exon 3 of STRN retaining a coiled-coil domain to exon 20 of ALK containing a kinase domain. The patient was treated with crizotinib and showed excellent clinical, radiographic, and molecular response. Repetitive dynamic ctDNA analysis revealed that the fraction of molecular alterations in plasma was closely associated with response to crizotinib treatment. This is the first clinical evidence involving advanced NSCLC due to a rare STRN-ALK fusion and has been effectively treated with crizotinib.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings: Innovations, Quality & Outcomes - Volume 1, Issue 1, July 2017, Pages 111-116
Journal: Mayo Clinic Proceedings: Innovations, Quality & Outcomes - Volume 1, Issue 1, July 2017, Pages 111-116
نویسندگان
Yan MD, PhD, Shu-Kui MD, PhD, Jian MD, Rui MD, Yu-Mei MD, Zong-Yu MD, Qiong MD, PhD,